Manufacturing News
Novo Nordisk, Pfizer Bidding War for Metsera Escalates to $10 Billion as FTC Raises Concerns
Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
6 November 2025